<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="119235">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01770470</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00045129</org_study_id>
    <nct_id>NCT01770470</nct_id>
  </id_info>
  <brief_title>Chitosan Chewing Gum Study in Dialysis Patients</brief_title>
  <official_title>A Pilot Study of Dietary Chitosan Chewing Gum in Dialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Maryland</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the pilot study is to determine the impact of short-term administration of
      chitosan-containing chewing gum on phosphate levels in patients with elevated serum
      phosphate levels.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The impact of using salivary phosphate binders in ESRD patients is not fully known. The
      purpose of the pilot study is to determine the impact of short-term administration of
      chitosan-containing chewing gum on phosphate levels in patients with elevated serum
      phosphate levels.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Serum phosphate</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Serum phosphate will be drawn 3 times per week over 2 weeks (during gum therapy), then once at 4 weeks and once at 6 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Salivary phosphate levels</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Salivary phosphate will be assessed 3 times per week over 2 weeks (during gum therapy), then once at 4 weeks and once at 6 weeks.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">15</enrollment>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>Patients receiving chronic hemodialysis</arm_group_label>
    <description>Dialysis patients chewing chitosan-containing gum</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Chitosan</intervention_name>
    <description>The product chitosan is contained in a chewing gum formulation</description>
    <arm_group_label>Patients receiving chronic hemodialysis</arm_group_label>
    <other_name>Chitosan</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Outpatient hemodialysis facility
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-64 years old

          -  ESRD receiving hemodialysis

          -  serum phosphate &gt; 6.0 mg/dL

        Exclusion Criteria:

          -  Unable to sign consent
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Dowling, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland, Baltimore County</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 15, 2013</lastchanged_date>
  <firstreceived_date>January 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland</investigator_affiliation>
    <investigator_full_name>Thomas Dowling</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>serum phosphate</keyword>
  <keyword>chitosan</keyword>
  <keyword>kidney disease</keyword>
  <keyword>salivary phosphate</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Chitosan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
